Business
Buyer Country Target Country Focus/assets Total value Details
Fujif_i lm Holdings Japan Toyama Chemical Japan pharmaceuticals $788 million
Galapagos Belgium Sareum’s drug discovery assets UK structure-based €695,000
drug discovery
Galderma Pharma Switzerland Collagenex Pharmaceuticals US dermatology $420 million
Galenica Switzerland Aspreva Pharmaceuticals Canada rare diseases $915 million
Gedeon Richter Hungary Pharmafarm Romania wholesaler Lei45.2 million
($19.5 million)
Genepharm Australasia Australia Strides Arcolab’s Australian & India manufacturing, N/A majority stake
Asian businesses distribution
Genmab Denmark PDL BioPharma US antibody $240 million
manufacturing plant manufacturing
Gerresheimer Germany EDP Spain packaging N/A
GlaxoSmithKline UK Reliant Pharmaceuticals US cardiovascular $1.65 billion
GlaxoSmithKline UK Sirtris Pharmaceuticals US metabolic disease $720 million
GlaxoSmithKline UK Bristol-Myers Squibb’s Egypt mature products $210 million
Egyptian business
GlaxoSmithKline UK Genelabs Technologies US hepatitis C $57 million
Healthcare Brands UK Antula Holdings Sweden OTC N/A
International
HemCon Medical US Alltracel Pharmaceuticals Ireland various N/A
Technologies
Hikma Pharmaceuticals Jordan Arab Pharmaceutical Manufacturing Jordan generics JD116 million
($164 million)
i3 US Lege Artis Russia CRO N/A
ICI UK Synkem (Laboratoires Fournier) France f_i ne chemicals N/A
Icon Ireland Healthcare Discoveries US clinical $22 million
pharmacology unit
Immunovaccine Canada Immunotope US immunotherapies N/A
Technologies
Intercell Austria Iomai US vaccines $189 million
International Drug France Eusa Pharma’s monoclonal France antibodies N/A
Development antibody research business
Invida Pharmaceutical Singapore Valeant Pharmaceuticals’ Asia-Pacif_i c Asia-Pacif_i c $37.8 million
Asia-Pacif_i c operations operations
Invitrogen US Applied Biosystems US life sciences $6.7 billion
Ipca Laboratories India Tonira Pharma India APIs Rs70-80 million 34% stake
($1.8-2.0 million)
Ipsen France Tercica US endocrinology $373 million
Ipsen France Vernalis Pharmaceuticals’ US business US neurology $17.5 million
Iris Pharma France Clirophtha France ophthalmology N/A
Jubilant Organosys India Draxis Health Canada speciality pharma, $255 million
contract
manufacturing
Jubilant Organosys India Speciality Molecules India intermediates $4.9 million
manufacturing
King Pharmaceuticals US Alpharma US speciality pharma $1.6 billion
Kirin Japan Kyowa Hakko Japan allergy, immunology, ¥300 billion
oncology ($2.63 billion)
Kyorin Pharmaceutical Japan Nisshin Kyorin Pharmaceutical Japan gastroenterology $31.8 million
Ligand Pharmaceuticals US Pharmacopeia US novel small molecules $55 million
Lilly US ImClone Systems US oncology $6.5 billion
Lilly US SGX Pharmaceuticals US oncology $64 million
Lupin India Hormosan Pharma Germany generics N/A
Lupin India Pharma Dynamics South Africa generics N/A 60% stake
Meda Sweden Recip Sweden infection SEK2.7 billion
($415 million)
Meda Sweden Valeant Pharmaceuticals’ eastern Europe various $425 million
and western European operations
Mediceo Paltac Holdings Japan Alfresa Holdings Japan wholesaler N/A merger due
to close April
2009
Medigen Biotechnology Taiwan Pacgen Biopharmaceuticals Canada infection, N/A
inf_l ammation
Mitsubishi Tanabe Pharma Japan Choseido Pharmaceutical Japan generics N/A
Neostem US Stem Cell Technologies US stem cells $940,000
Newron Pharmaceuticals Italy Hunter-Fleming UK development €8 million €21.7 million
compounds
Nicholas Piramal India Healthline’s pharmaceuticals India custom Rs150 million
business manufacturing ($3.8 million)
Novartis Switzerland Alcon US/ eye care $10.4 billion 25% stake, to
Switzerland be followed
by 52%
acquisition for
total deal worth
$38 billion
Novartis Switzerland Protez Pharmaceuticals US antibiotics $100-400
million
Novartis Switzerland Nektar Therapeutics’ US pulmonary drug $115 million
pulmonary drug delivery delivery
business unit
www.scripnews.com/supplements Scrip 100
21
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128